Space Drug Discovery Part 5: Future Scenarios for Space Drug Discovery – How Will the Pharmaceutical Industry Change in 10 Years?
Part 5: Future Scenario – The Space Drug Discovery Market after 10 years.
Introduction: In 2035, will the pharmaceutical industry operate on the premise of 'space data'?
2035.
Although it is only 10 years from now, the drug discovery and medical industry may have established a
pharmaceutical industry based on space data due to the development of space technology, space stations, and AI-driven drug discovery.
In this article, we predict the future of space drug discovery in the following four areas:
Scientific Frontier
Industrial Landscape
Regulatory & Policy
Societal Impact
1. Scientific Future: Space as the 'Standard for Aging and Disease Models'
The human body changes shown by space medicine are already attracting attention from the medical community, but by 2035,
the space environment may become a 'standard disease model platform'.
1) Space aging models will become the 'gold standard'
Aging phenomena that take years on Earth progress in weeks to months in space.
By 2035:
Screening for anti-aging and anti-inflammatory drugs
Standardization of biomarkers of aging
Training data for aging AI models
Space-derived data will be utilized globally for these purposes.
→ Medical research for an aging society will not be viable without space data.
2) Explosive development of microgravity x iPS cell research
Microgravity has a strong influence on cell differentiation and maturation.
In 2035:
High-precision organoid generation from iPS cells
Promotion of vascularization and neural differentiation
High-precision construction of tumor models
Development platform for stem cell therapeutics
and other such developments, a future is emerging where the space environment is utilized as a foundational technology for cell therapy.
3. Space Radiation × DNA Repair Research Opens Up New Disease Understanding
Space radiation differs completely in quality (energy, particles) from radiation on Earth.
In 2035:
Discovery of novel factors in DNA repair mechanisms
Research on side effects of cancer treatment
Expansion of research on radiation-resistant organisms
A new field called CRE (Cancer Radiation Engineering)
is expected to be born.
2. Future of the Industry: Space CRO/CDMOs Become 'Commonplace'
In the 2035 drug discovery industry, research and data acquisition using the space environment will be
fully established as a sector of CRO/CDMO services.
1. Era of Joint Labs between Private Space Stations and Pharmaceutical Companies
As private stations become widespread as successors to the ISS:
Pharmaceutical companies will have their 'own space labs'
CROs will install dedicated modules in space orbit
Labs where autonomous robots conduct experiments 24 hours a day
will become commonplace.
Corporate profiles that could exist in 2035
“Space Pharma CRO Japan”
“Orbital Drug Discovery Labs”
“Microgravity CDMO Global”
Space will become part of the pharmaceutical infrastructure.
(2) Space data AI platforms will become a massive market
Among AI drug discovery companies in 2035,
those that do not use space data will be at a disadvantage in market competition will occur.
The reasons are:
Terrestrial aging models are incomplete
Space data is scarce and extremely valuable
Space “extreme environment data” is effective for AI training
→ competition for rare data will occur, and the price of space data may skyrocket.
(3) The new industry of “space manufacturing”: The era of making pharmaceuticals in space
In a microgravity environment,
uniform cell growth
homogeneous formation of nanoparticles
stabilization of proteins
higher quality of crystals
There are multiple phenomena advantageous to pharmaceutical manufacturing, such as these.
By 2035:
"Space-manufactured biopharmaceuticals"
"Space nanocarriers"
"Antibody drugs manufactured in orbit"
are highly likely to emerge.
3. The Future of Regulation: International Standardization of Space Data and Space GMP
As space drug discovery progresses, the development of international regulations will become essential.
By 2035, the following may be standardized:
1. Birth of Space GMP (Good Manufacturing Practice)
For pharmaceuticals manufactured in orbit, the following will be established as international rules:
Management standards for unmanned robotic laboratories
Stability evaluation of formulations derived from space radiation
Temperature and vibration conditions during transport
Recovery process from space to Earth
Preliminary discussions on these are currently underway at the international conference level.
2. Establishment of Space Bioethics
Especially regarding human cells, AI medicine, and genetic analysis:
Handling of human-derived cells in space
Ethics of aging models
Ownership of space-derived data
Unification of cross-border medical ethics
and other topics will be discussed.
3. The possibility of Japan becoming the center of international rule-making
The reasons are:
Operational track record of the Kibo module
Accumulation of space radiation research
Strong pharmaceutical and medical industries
International influence on pharmaceutical regulations (presence in ICH)
→ Japan can stand at the center of the world in rule-making.
4. Future of society: "Space medical achievements will save Earth's healthcare"
By 2035, knowledge gained in space will be
directly used to solve medical challenges on Earth.
1. Aging research: Space data promotes new drug development
Sarcopenia
Osteoporosis
Immune aging
Cognitive decline
Lifestyle-related diseases
Space data will be useful for challenges in a super-aging society, such as these.
2. Lifestyle-related diseases: Research on metabolism and energy metabolism will advance
ISS research has confirmed that dramatic changes occur in metabolism.
By 2035:
Novel diabetes drugs
Metabolic control drugs
Anti-obesity drugs
Energy metabolism models
are highly likely to have emerged from space research.
(3) Regenerative Medicine: Cells and tissues cultured in space will play an active role on Earth
In a microgravity environment, the following are improved:
Uniform growth of 3D tissues
Angiogenesis
Myocardial and neural differentiation
Stem cell retention
By 2035, it is conceivable that "space-derived cells and tissues" will be used in regenerative medicine products.
Conclusion: In 2035, space drug discovery will become an "essential infrastructure" for the pharmaceutical industry
Drug discovery in 2035 will:
Utilize space data
Use space CRO/CDMO services
Make space AI platforms the standard
Adopt space GMP as an international regulation
Space disease models become the center of drug efficacy evaluation
There is a possibility that we will move toward such a future.
Space will not just be a "dream research environment," but will become a
practical infrastructure that advances medicine on Earth.
In the next installment (Part 6), we will focus on policy, international cooperation, and rule-making, and explain how Japan should take leadership.
---------------------------------------------------------
[English Version] (Approx 2,500 words)
---------------------------------------------------------
Introduction: Will Pharma in 2035 Be “Space-Data-Native”?
By 2035—just 10 years from now—the global pharmaceutical ecosystem may rely fundamentally on data generated in space.
This article explores four dimensions of that future:
Scientific
Industrial
Regulatory
Societal
1. Scientific Future: Space as the Standard Disease Model Platform
1. Space Aging Models Become the Gold Standard
Space accelerates aging-like changes dramatically, enabling:
Rapid anti-aging screening
Standardized aging biomarkers
AI aging-model training data
Aging research will depend on space datasets.
2. Microgravity × iPS Cell Biology
Microgravity affects differentiation, maturation, angiogenesis, and tumor modeling.
By 2035, space-based cell biology may be integrated into:
Organoid generation
Regenerative medicine
Oncology modeling
Stem-cell therapeutics
3. Space Radiation × DNA Repair Biology
Space radiation is fundamentally different from terrestrial radiation.
By 2035, we may see:
New DNA-repair pathway discoveries
Insights into cancer radiotoxicity
Radiation-resistant organism studies
A new field: Cancer Radiation Engineering (CRE)
2. Industrial Future: Space CRO/CDMO Becomes Standard
1. Joint Orbital Labs Between Pharma and Private Stations
Commercial stations allow:
Pharma-owned orbital labs
CROs operating dedicated microgravity modules
Autonomous robotic laboratories
2. Space Data AI Platforms
Space data becomes a premium asset for AI models.
Companies lacking space data lose competitive advantage.
3. Space Manufacturing of Biopharmaceuticals
Microgravity benefits manufacturing:
Uniform nanoparticle formation
Stable protein structures
High-quality crystal formation
Leading to space-manufactured biologics.
3. Regulatory Future: Space-GMP and Bioethics
1. Space-GMP
International standards for:
Robotic labs
Radiation-driven stability
Orbital-to-Earth logistics
2. Space Bioethics
New frameworks for:
Human-cell use in space
Data ownership
Cross-border medical regulation
3. Japan’s Leadership
Japan’s strengths:
Kibo module operations
Space radiation expertise
Strong pharma industry
ICH leadership
Japan may lead global rule-making.
4. Societal Future: Space Medicine Benefits Earth Directly
1. Aging Research
Space data drives:
Sarcopenia therapeutics
Osteoporosis drugs
Immunosenescence treatments
Cognitive decline studies
2. Metabolic Diseases
Space accelerates metabolic shifts, enabling new treatments for:
Diabetes
Obesity
Metabolic syndrome
3. Regenerative Medicine
Space-derived tissues and cells may support:
Heart regeneration
Neural repair
Organogenesis
Conclusion: By 2035, Space Will Be a Core Infrastructure for Global Pharma
Space-enabled data, manufacturing, and disease models will become essential parts of:
Drug discovery
Preclinical evaluation
AI modeling
Manufacturing
Global regulation
Space will not be a frontier but a fundamental medical infrastructure.
🔵 Part 4: Space Medicine and the Potential for Drug Discovery Startups (Full Version, approx. 4,800 characters)
🔵 Part 4: Space Medicine and Startup Opportunities (Full Article)
---------------------------------------------------------
[Japanese Version] (approx. 2,500 characters)
Introduction: Why is space medicine suited for startups?
Within the field of space drug discovery,
**Space Medicine** is rapidly gaining attention as a field where university-originated startups and small-scale ventures can enter more easily than large corporations.
The reasons are clear:
Data obtained in the space environment cannot be acquired on Earth
Directly linked to massive markets such as aging, immunity, and muscle atrophy
Easy to facilitate collaboration between AMED, JAXA, and universities
Costs are dramatically reduced through platform-based experimental opportunities
The narrative appeal of "space" makes it easier to attract investors and companies
In this article, we will delve deeply into the scientific value of space medicine and the actual business models of drug discovery ventures.
1. Scientific Value of Space Medicine: "Accelerated Human Body Changes" Demonstrated by Astronauts
The most important aspect of space medicine is the
"biological changes that can never be reproduced on Earth" shown by astronaut health data.
On the ISS, the following changes are confirmed in just a few weeks to a few months:
■ Human body changes accelerated in space
Muscle atrophy: Several years' worth of Earth-equivalent change in one month
Bone density loss: 1-2% decrease every month
Decline in immune function: Disruption of inflammatory cytokines
Changes in optic nerve pressure: SANS (Spaceflight-Associated Neuro-ocular Syndrome)
Increased DNA damage rate: Impact of space radiation
General aging-like phenomena: Increase in cellular senescence markers
These changes are directly linked to
aging research, metabolic diseases, immune diseases, and regenerative medicine.
2. Value for Drug Discovery Ventures: Verification Speed is "Over 10 Times Faster Than on Earth"
Generally, aging models and immune disease models require evaluations over
years in animals or humans.
However, in space, because environmental stress is extremely high,
"aging data" can be obtained in a few weeks
even shorter periods for cells and iPS cells
acceleration of disease model construction
target discovery becomes orders of magnitude faster
For drug discovery ventures, this means
compressing time (Time-to-data) = increasing competitiveness
.
3. Four types of ventures utilizing space medical data
Drug discovery ventures commercializing space medical data can be mainly classified into the following four types.
① Target Discovery Ventures (Space Target Discovery)
A model that analyzes
gene expression data
signal transduction
metabolic changes
cellular aging markers
obtained in the space environment to find new targets.
Business examples
Inflammatory pathways observed only in the space environment
Novel molecular targets for osteoporosis
Discovery of therapeutic targets in accelerated aging models
→ Easy to collaborate with AI drug discovery companies.
(2) Space Disease Models × Drug Discovery Evaluation Ventures
Utilize "disease-like changes" obtained in space for drug efficacy evaluation.
Application examples
Screening for anti-muscle atrophy drugs
Evaluation of immunostimulants
In vivo / ex vivo evaluation of bone formation promoters
Drug discovery evaluation using space-exposed iPS cells
It has been pointed out that space disease models have the potential to become the
gold standard in the aging research market
.
(3) Space Data Analysis × AI Drug Discovery Companies
Big data acquired in space is extremely compatible with AI analysis.
What becomes possible with AI
Discovery of novel markers
Pathway analysis
Repositioning of existing drugs
Mechanism elucidation
Construction of integrated models for aging indicators
Space × AI is predicted to become mainstream in the 2030s.
(4) Ventures for equipment that reproduces the space environment on the ground
The most "profitable on the ground" business area.
Development Targets
Microgravity Simulation Equipment
Space Radiation Simulation Equipment
Partial Gravity Devices
Space Closed Environments (Artificial Ecosystems)
Sales to university, pharmaceutical, and regenerative medicine researchers are expected.
4. How to Proceed with Commercialization in Japan: The Shortest Route
Japan possesses one of the world's leading foundations in space medicine.
■ Execution Steps (Recommended)
JAXA 'Kibo' Utilization × University-led Research
Acquire private experimental slots using Space BD
Analyze acquired data to identify target candidates
Joint research with AI drug discovery companies
Secure research funding from AMED and NEDO
Early consultation with PMDA to build a regulatory strategy
Move toward joint development with pharmaceutical companies
■ Japan's Strengths
World-class microgravity experimental results
Accumulated research on space radiation
Participation of numerous national universities and research institutes
A strong culture of industry-academia collaboration
→ One of the "most suitable countries for launching space medical ventures".
5. Business models for venture entry
Ventures specializing in space medicine can grow by combining the following revenue structures.
① Data licensing (Space big data)
High scarcity value and high unit price.
② Joint research with pharmaceutical companies
Space disease models × AI analysis × Target discovery
③ Contract research (Space CRO)
Acting as an agent for space experiments for universities and companies.
④ Sales of ground-based equipment
Stable sales of simulated gravity and radiation equipment.
⑤ AMED/NEDO research grants
Easy to secure initial funding.
→ Multiple revenue streams that can sustain a venture.
Conclusion: Space medicine is the "shortest path to a deep space industry" where ventures can capture the global market.
Space medicine is,
aging
immunity
regenerative medicine
Metabolic diseases
While directly linked to massive medical markets, it also possesses the
storytelling potential and data value inherent to the unexplored frontier of space.
Space medicine × drug discovery ventures have the potential to become
a central domain of the next-generation pharmaceutical industry.
[English Version]
Introduction: Why Space Medicine Is “Startup-Friendly”
Among all areas of space drug discovery, space medicine is particularly accessible to startups and university spin-offs.
The reasons are clear:
Space generates biological data impossible to obtain on Earth
The changes map directly to massive markets (aging, immunity, metabolism)
Access to experiments is becoming cheaper and standardized
Collaboration with agencies (JAXA, NASA) is increasingly feasible
“Space × Healthcare” has strong storytelling power that attracts investors
This article explores both the scientific foundation and real business pathways.
1. The Scientific Value of Space Medicine: Accelerated Human Biology
Astronaut health data reveals dramatic biological changes that are impossible to reproduce on Earth.
Within weeks to months in orbit, astronauts show:
Muscle atrophy equivalent to years of aging
Bone density loss of 1–2% per month
Immune dysregulation
Neuro-ocular pressure changes (SANS)
DNA damage from cosmic radiation
Broad aging-like phenomena
These accelerated changes create unique disease models for pharma.
2. Value to Startups: 10× Faster Validation
Traditional models for aging, immunity, or metabolism require months to years.
Space compresses these timelines:
Aging signatures in weeks
Disease-like cellular phenotypes rapidly
Faster target identification
Early proof-of-concept data
This gives startups enormous competitive advantage.
3. Four Types of Startups in Space Medicine
1. Target Discovery Startups
Using space-induced
gene expression, metabolism, signaling, and aging markers to find new targets.
2. Space Disease Model–Based Therapeutics Startups
Using space-acquired disease-like models for drug screening and efficacy evaluation.
3. Space Data × AI Drug Discovery Companies
Analyzing rare, high-value datasets for pathway discovery or drug repositioning.
4. Ground Simulation Technology Startups
Developing microgravity simulators, radiation systems, and partial gravity devices.
4. How to Build a Space-Medicine Startup in Japan
Japan is one of the best positioned countries due to its infrastructure.
Recommended steps
Use the Kibo module via JAXA
Launch via Space BD commercial framework
Analyze acquired data to identify targets
Partner with AI drug discovery firms
Secure AMED/NEDO grants
Engage early with PMDA
Co-develop with pharmaceutical companies
Japan combines
strong academic base
unique microgravity research track record
supportive national programs
5. Business Models for Space-Medicine Startups
Startups can combine multiple revenue sources:
Data licensing
Joint research with pharma
Contract space experiments (Space CRO)
Ground equipment sales
Public grants
A diverse revenue stack enables scalability.
Conclusion
Space medicine is a rare field where
scientific novelty, market size, and startup agility
intersect perfectly.
It represents one of the shortest pathways from laboratory discovery to global business in the space pharmaceutical industry.
この記事は noteマネー にピックアップされました
